Literature DB >> 3737273

Pharmacokinetics of intravenous clindamycin in newborn infants.

G Koren, Y Zarfin, D Maresky, T E Spiro, S M MacLeod.   

Abstract

We studied 12 newborn infants (gestational ages 26-39 wk [mean +/- SD, 30.6 +/- 4.7]; birth weight 640-2700 g, [mean, 1,322 +/- 688]; postnatal age 1-24 days [mean, 9.6 +/- 8.5]) who received clindamycin phosphate for suspected or proven necrotizing enterocolitis (ten patients) or suspected anaerobic septicemia (two patients) in doses of 3.2-11 mg/kg every six hours. Range of mean serum concentration of clindamycin at steady state was between 12.7 and 40 micrograms/ml (therapeutic range = 2-10 micrograms/ml). High concentrations could be attributed to elimination T1/2 (6.3 +/- 2.1 hr) 100% longer than in older children or adults. Clindamycin clearance (61.6 +/- 31.6 hr ml/kg/hr) was lower than in older children or adults. Because of the observed prolongation in T1/2 and correspondingly lower clearance, the IV dose of clindamycin in newborn infants should be reduced to 15-20 mg/kg/day given in four daily doses.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3737273

Source DB:  PubMed          Journal:  Pediatr Pharmacol (New York)        ISSN: 0270-322X


  7 in total

Review 1.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 3.  Dosing in neonates: special considerations in physiology and trial design.

Authors:  Lawrence C Ku; P Brian Smith
Journal:  Pediatr Res       Date:  2014-09-30       Impact factor: 3.953

4.  Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants.

Authors:  Daniel Gonzalez; Paula Delmore; Barry T Bloom; C Michael Cotten; Brenda B Poindexter; Elisabeth McGowan; Karen Shattuck; Kathleen K Bradford; P Brian Smith; Michael Cohen-Wolkowiez; Maurine Morris; Wanrong Yin; Daniel K Benjamin; Matthew M Laughon
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.938

5.  Dosing antibiotics in neonates: review of the pharmacokinetic data.

Authors:  Nazario D Rivera-Chaparro; Michael Cohen-Wolkowiez; Rachel G Greenberg
Journal:  Future Microbiol       Date:  2017-07-31       Impact factor: 3.553

6.  A Pharmacoepidemiologic Study of the Safety and Effectiveness of Clindamycin in Infants.

Authors:  Rachel G Greenberg; Huali Wu; Anil Maharaj; Michael Cohen-Wolkowiez; Kay M Tomashek; Blaire L Osborn; Reese H Clark; Emmanuel B Walter
Journal:  Pediatr Infect Dis J       Date:  2020-03       Impact factor: 3.806

7.  Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents.

Authors:  D Gonzalez; C Melloni; R Yogev; B B Poindexter; S R Mendley; P Delmore; J E Sullivan; J Autmizguine; A Lewandowski; B Harper; K M Watt; K C Lewis; E V Capparelli; D K Benjamin; M Cohen-Wolkowiez
Journal:  Clin Pharmacol Ther       Date:  2014-06-20       Impact factor: 6.903

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.